Hims & Hers Health (NYSE:HIMS) Insider Sells $308,767.81 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Irene Becklund sold 8,411 shares of the stock in a transaction on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total value of $308,767.81. Following the sale, the insider directly owned 2,126 shares in the company, valued at $78,045.46. This trade represents a 79.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $35.49 on Friday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The firm has a market cap of $8.08 billion, a price-to-earnings ratio of 65.72, a price-to-earnings-growth ratio of 7.03 and a beta of 2.41. The business has a 50-day simple moving average of $41.85 and a two-hundred day simple moving average of $48.49. Hims & Hers Health, Inc. has a fifty-two week low of $23.97 and a fifty-two week high of $72.98.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.03). Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The firm had revenue of $598.98 million for the quarter, compared to the consensus estimate of $578.99 million. During the same period in the previous year, the company earned $0.32 earnings per share. Hims & Hers Health’s quarterly revenue was up 49.2% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Hims & Hers Health declared that its Board of Directors has authorized a stock buyback program on Monday, November 17th that allows the company to repurchase $250.00 million in outstanding shares. This repurchase authorization allows the company to buy up to 3% of its stock through open market purchases. Stock repurchase programs are often a sign that the company’s leadership believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of analysts have commented on HIMS shares. Bank of America upped their target price on shares of Hims & Hers Health from $28.00 to $32.00 and gave the company an “underperform” rating in a report on Tuesday, November 4th. BTIG Research reissued a “buy” rating and set a $85.00 price objective on shares of Hims & Hers Health in a research report on Tuesday, November 4th. KeyCorp started coverage on Hims & Hers Health in a research note on Tuesday, October 21st. They issued a “sector weight” rating for the company. Leerink Partnrs upgraded Hims & Hers Health from a “hold” rating to a “strong-buy” rating in a research report on Thursday, December 4th. Finally, UBS Group set a $32.00 price target on Hims & Hers Health in a report on Tuesday, November 4th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $45.50.

Hims & Hers Health News Roundup

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers announced a roughly US$200 million investment to expand its New Albany, Ohio operations — a move reporters say could quietly redefine its core strategy by expanding fulfillment/operational capacity and creating ~400 jobs. Investors often view large, strategic capacity investments as potential drivers of revenue growth and margin improvement over time. Is Hims & Hers Health’s US$200 Million Ohio Bet Quietly Redefining Its Core Strategy (HIMS)?
• Positive Sentiment: The company has an active share-repurchase program — the board authorized up to $250M (about 3% of shares) — which can support the stock by reducing float and signaling management confidence in valuation. Hims, Block, and NRG Just Launched Huge Stock Buybacks
• Neutral Sentiment: Analyst / media cautions: a Zacks piece flagged HIMS among high-growth medtech/telehealth names that could slow in 2026 — a reminder that momentum names carry execution and multiple-compression risk. 3 Skyrocketing MedTech Stocks That Might Lose Steam in 2026
• Neutral Sentiment: Large institutional ownership remains significant (e.g., Farallon, Invesco increased stakes), which can stabilize share demand but also concentrate price action; this is background context for liquidity and investor flows. HIMS company page (MarketBeat)
• Negative Sentiment: Several insiders sold shares on Dec. 17 (including Deborah Autor, Irene Becklund, Patrick Carroll and COO Michael Chi) — transactions together total roughly $1.4M+ and include large percentage reductions for some insiders. Concentrated insider selling, particularly from senior executives, can spook momentum traders and suggests some tax/liquidity-driven exits or portfolio trimming. Hims & Hers Health (NYSE:HIMS) Insider Sells $258,952.34 in Stock

Institutional Investors Weigh In On Hims & Hers Health

A number of institutional investors have recently bought and sold shares of the business. Quent Capital LLC purchased a new position in shares of Hims & Hers Health in the third quarter valued at about $28,000. Binnacle Investments Inc bought a new stake in Hims & Hers Health during the 3rd quarter valued at approximately $28,000. Virtus Advisers LLC purchased a new position in Hims & Hers Health in the 2nd quarter worth approximately $26,000. Quaker Wealth Management LLC bought a new position in Hims & Hers Health in the 2nd quarter worth approximately $29,000. Finally, Bessemer Group Inc. grew its holdings in Hims & Hers Health by 105.8% during the 2nd quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock valued at $30,000 after buying an additional 312 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.